摘要
容量管理仍是目前充血性心力衰竭治疗面临的主要挑战,也是缓解急性充血症状的主要治疗手段。精氨酸血管加压素2型受体拮抗剂托伐普坦作为新型利尿剂,在充血性心力衰竭患者的容量管理中发挥了独特的作用。本文对托伐普坦治疗心力衰竭的作用机制、相关临床试验、适用人群、启动治疗的时机和剂量、安全性和治疗反应性等问题进行了回顾,旨在推动托伐普坦在充血性心力衰竭中的合理应用。
Volume management is still the main challenge in the treatment of congestive heart failure,and is the main treatment for alleviating acute congestive symptoms.Tolvaptan,one of the arginine vasopressin type 2 receptor antagonists,has been used to treat congestive heart failure patients as a novel diuretic agent with unique effects.This review summarizes issues including the mechanism of action,recent clinical studies,target patients,optimal initiation timing and dose,as well as safety and response of tolvaptan in congestive heart failure,aims at rational utilization of the agent.
作者
阴大伟
崔华
YIN Da-wei;CUI Hua(Department of Geriatric Cardiology,The Second Medical Center of Chinese PLA General Hospital,National Clinical Research Center for Geriatric Diseases,Beijing 100853,China)
出处
《临床药物治疗杂志》
2019年第10期19-23,51,共6页
Clinical Medication Journal
